// App-Quantinova.ai

P191 : Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from COAST-V trial

Researchers

Presenter

  • Sofia Ramiro

Principal Investigators

  • Cedric Lukas

  • Michael Nissen

  • Yves Schymura

  • Khai Jing Ng

  • Andrew Bradley

  • Gabriel Doridot

  • Soyi Liu-Leage

  • Antoni Chan

  • Cheng-Chung Wei

Medical Centers

  • Neonatal Unit, Royal Berkshire Hospital, Reading, United Kingdom

  • Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan

  • University Hospital Centre Montpellier, University of Montpellier, Montpellier, France

  • Centre of Oncology, Geneva University Hospital, Geneva, Switzerland

  • Hematology, Leiden University Medical Center, Leiden, The Netherlands,

Locations

  • United Kingdom

  • Switzerland

  • Taiwan

  • Netherlands

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved